LAG3 and melanoma: At the 2021 ASCO Annual Meeting, preliminary data on clinical activity from two expansion cohorts of patients with advanced melanoma [anti–PD-(L)1 naive or experienced] who were treated with fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, and cemiplimab were presented.